IMUNON Files IND Application to Begin Human Testing of IMNN-101
Company expects enrollment in Phase 1 proof-of-concept study of DNA-based vaccine technology to begin in Q2The application follows guidance provided...
Company expects enrollment in Phase 1 proof-of-concept study of DNA-based vaccine technology to begin in Q2The application follows guidance provided...
International Society for Cell & Gene Therapy (ISCT) Names Dr. Lowdell with the Career Achievement Award in Cell and Gene Therapy...
Preliminary results from ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS on track for 1H 2024Preliminary data from ADVANCED-2...
Announced Positive Results from Second Cohort of Phase 1 Trial of Decoy20 Initiating Multi-Dosing for patients with solid tumors NEW...
Company to host conference call and webcast on Wednesday, March 27th at 8:30am EDT LYON, France, March 13, 2024 --...
ZYNLONTA® (loncastuximab tesirine-lpyl) net sales of $16.6 million in 4Q 2023 and $69.1 million for full year (FY) 2023; 4Q...
STAFFORD, Texas, March 13, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused...
NORTHAMPTON, MA / ACCESSWIRE / March 12, 2024 / We're committed to increasing diverse representation in clinical trials, especially for...
MIAMI, March 12, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently...
Allogene’s AlloCAR T™ Autoimmune Disease Platform Leverages Arbor’s CRISPR Gene-Editing TechnologyFirst Allogeneic CAR T Phase 1 Clinical Trial in Autoimmune...
MitoCareX Bio dedicates efforts to creating a predictive AI model to predict small molecules more efficiently TEL AVIV, Israel, March...
BERKELEY, Calif. and MAINZ, Germany, March 12, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”),...
Integrated Diagnostics Pathology Scanner Digital Pathology March 12, 2024 Cloud offering will help improve workflow integration, access, and reliability, delivering...
MIAMI, March 12, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing...
Dosed first patient in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLCClinical data on track for...
IK-930 continues to advance in the clinic now with an optimized formulation with improved pharmacokinetics IK-930 clinical update planned for...
Tonix recently reported results from second positive Phase 3 trial of Tonmya™ for the management of fibromyalgia In the U.S.,...
HUMMELSTOWN, Pa., March 12, 2024 (GLOBE NEWSWIRE) -- SIRPant Immunotherapeutics, Inc., a clinical-stage immuno-oncology company focusing on developing next-generation macrophage-based...
NORCROSS, Ga., March 12, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target...
KNOXVILLE, TN, March 12, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that...